Custom Truck One Source (CTOS) Q1 2025 Earnings Call May 01, 2025 09:00 AM ET Company Participants Brian Perman - Vice President, Investor RelationsRyan McMonagle - Chief Executive OfficerChris Eperjesy - CFONaim Kaplan - Equity Research Associate Conference Call Participants None - AnalystRohan Vasudeva - Equity Research Analyst Operator Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Custom Truck OneSource Inco ...

Custom Truck One Source (CTOS) Q1 2025 Earnings Call May 01, 2025 09:00 AM ET Company Participants Brian Perman - Vice President, Investor RelationsRyan McMonagle - Chief Executive OfficerChris Eperjesy - CFONaim Kaplan - Equity Research Associate Conference Call Participants None - AnalystRohan Vasudeva - Equity Research Analyst Operator Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Custom Truck OneSource Inco ...

Custom Truck One Source (CTOS) Q1 2025 Earnings Call May 01, 2025 09:00 AM ET Speaker0 Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Custom Truck OneSource Incorporated First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I will now hand the call over to your host t ...

Core Viewpoint - MGIC Investment Corporation reported strong financial results for the first quarter of 2025, demonstrating continued performance improvement and market leadership despite macroeconomic concerns [2][3]. Financial Performance - Net income for Q1 2025 was $185.5 million, or $0.75 per diluted share, compared to $184.7 million and $0.72 per diluted share in Q4 2024, and $174.1 million and $0.64 per diluted share in Q1 2024 [4]. - Adjusted net operating income for Q1 2025 was $185.2 million, or $0.75 per diluted share, reflecting a slight increase from $184.5 million and $0.72 per diluted share in Q4 2024, and $178.4 million and $0.65 per diluted share in Q1 2024 [4]. - New insurance written (NIW) was $10.2 billion in Q1 2025, down from $15.9 billion in Q4 2024 and up from $9.1 billion in Q1 2024 [4][20]. - Net premiums earned were $243.7 million, slightly up from $241.3 million in Q4 2024 and $242.6 million in Q1 2024 [4]. - The annual persistency rate was 84.7%, a slight decrease from 84.8% in Q4 2024 and 85.7% in Q1 2024 [4]. Capital and Liquidity - As of March 31, 2025, PMIERs available assets were $5.9 billion, with PMIERs excess at $2.6 billion [4]. - The holding company liquidity was reported at $824 million, down from $1,076 million at the end of Q4 2024 [4]. Shareholder Actions - The company repurchased 9.2 million shares for $224.3 million and an additional 2.8 million shares for $65.8 million through April 25, 2025 [7]. - A dividend of $0.13 per common share was declared, payable on May 21, 2025 [7]. Delinquency and Loss Metrics - Primary delinquency inventory stood at 25,438, down from 26,791 in Q4 2024 [4][24]. - The primary IIF delinquency rate was 2.30%, a decrease from 2.40% in Q4 2024 [4][24]. - Losses incurred, net, were $9.6 million, compared to $8.7 million in Q4 2024 and $4.6 million in Q1 2024 [4]. Market Position and Strategy - The company maintains a strong market position with robust capital and liquidity, allowing it to continue executing its business strategies and supporting customers with innovative solutions [2][3].

AB “Ignitis grupė” (hereinafter – the Group) informs that on 30 April 2025 the National Energy Regulatory Council (hereinafter – NERC) passed a resolution “On the amendment of the National Energy Regulatory Council's Resolution No. O3-229 of 14 September 2012 ‘On the approval of the methodology for determining the electricity price and the price for reserve capacity and isolated system operation services’” (link in Lithuanian) (hereinafter – the Resolution), which adopted the new mechanism for distributing ...

Company Overview - Avalo Therapeutics, Inc. is a clinical stage biotechnology company focused on the treatment of immune dysregulation [3] - The company's lead asset is AVTX-009, an anti-IL-1β monoclonal antibody targeting inflammatory diseases [3] Product Information - AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity [4] - IL-1β is a central driver in the inflammatory process, and its overproduction is implicated in many autoimmune and inflammatory diseases [4] - Inhibition of IL-1β could be effective in treating conditions such as hidradenitis suppurativa and various inflammatory diseases in dermatology, gastroenterology, and rheumatology [4] Upcoming Events - Dr. Garry Neil, CEO of Avalo, will present at the Citizens Life Sciences Conference in New York on May 8, 2025, at 3:00 pm ET [1]

Paccar (PCAR) Q1 2025 Earnings Call April 29, 2025 04:16 PM ET Speaker0 Good morning, and welcome to PACCAR's First Quarter twenty twenty five Earnings Conference Call. All lines will be in listen only mode until the question and answer session. Today's call is being recorded. And if anyone has an objection, you should disconnect at this time. I would now like to introduce Mr. Ken Hastings, PACCAR's Director, Investor Relations. Mr. Hastings, please go ahead. Speaker1 Good morning. We would like to welcome ...

Altria Group (MO) Q1 2025 Earnings Call April 29, 2025 09:00 AM ET Company Participants Mac Livingston - VP, IR, Altria Client ServicesBilly Gifford - CEOSal Mancuso - EVP and CFOMatthew Smith - Director - Food & TobaccoGaurav Jain - Head of EU SMID, EU packaging, and Global Tobacco and CannabisBonnie Herzog - Managing Director Faham Baig - Executive Director - Equity Research Conference Call Participants Emma Rumney - Analyst Operator Good day, and welcome to the Altria Group twenty twenty five First Quart ...

好久没给大家聊楼市了，最近看到好些小伙伴想听听国内地产，加上最近不少报道说是房价上涨了，那今天咱们就来聊聊国内地产：为什么现在都在说房 价上涨了？真实的楼市情况如何？楼市今年走势会是什么样？普通人要不要上车？ 先来说说最近不少房产博主，以及媒体都在吹风房价上涨。 这事根据堂主的观察，有两个原因。 第一个原因是最新的楼市数据出来了。 上周统计局发布2025年3月份的楼市数据。 70个大中城市中，新建商品住宅销售价格环比上涨的有24个，比上月增加6个； 二手住宅环比上涨城市有10个，比上月增加7个。 这个数据看起来挺不错的， 但是，代表楼市风向标的四个一线城市，数据却很不统一 一手房方面，上海和深圳分别上涨0.7%和0.1%，北京和广州则分别下降0.2%和0.1%。 二手房方面，北京、上海、深圳分别上涨0.5%，0.4%和0.3%，广州则是下降0.2%。 | | 城市 | 环比 | 同比 | 1-3月平均 | | | 环比 | 同比 | 1-3月平均 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 上年同月 | 上年同 ...

Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA. These presentations include Phase III clinical data for leniolisib for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) and insights into APDS and additional p ...